Analyte Data

Analyte DataAnalyte Data2Analyte Data3

 

Targeted & Unbiased Analyte data can be downloaded from the following studies using the Query Tool

alpha-Synuclein (total, filament and phosphorylated)

  1. Evaluation of Glucocerebrosidase Pathway Biomarkers in Parkinson Disease-ELISA- Serum/CSF (alpha-Syn).  PI: Rachel Saunders-Pullman
     
  2. Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease (CSF).  PI: David Walt 
     
  3. Large Scale Biomarker Discovery and Validation for Parkinson's Disease- Luminex-CSF(Tau, pTau, alpha-Syn, Abeta).  PI: Jing Zhang

Tau (total and phosphorylated)

  1. Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease (CSF).  PI: David Walt 
     
  2. Large Scale Biomarker Discovery and Validation for Parkinson's Disease- Luminex-CSF(Tau, pTau, alpha-Syn, Abeta).  PI: Jing Zhang

beta-amyloid (1-40, 1-42)

  1. Amyloid Burden in patients with Dementia with Lewy Bodies-Lumipulse G-CSF (beta-amyloid) PI: Diana Ziegler

DJ-1

  1. Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease (CSF).  PI: David Walt

C-Reactive Protein

IL-6

  1. Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease (CSF).  PI: David Walt

Neurofilament Light

  1. Detection of Post-Translationally Modified Proteins as a Biomarker Panel for Parkinsons Disease (CSF).  PI: David Walt

PD2 peptoid

  1. Diagnostic and prognostic biomarkers for Parkinson's disease-ELISA-Serum(Peptoid). PI: Dwight German & Richard Dewey

Ferritin

  1. Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's disease-ELISA-CSF/Plasm/Serum(Ferritin).  PI: Xuemei Huang

Vitamin D (D2, D3)

  1. Johns Hopkins Medicine Biomarker Discovery in Parkinson's Disease-LC/MS/MS-Plasma (Vitamin D).  PI: Ted Dawson

Beta-glucosidase

  1. Beta-glucocerebrosidase activity in whole blood of patients with Lewy body dementias, disease controls, and healthy controls.  PI: Clemens Scherzer

IgG Index

  1. Adaptive immune response and cognition in Parkinson’s Disease-ELISA-Plasma/CSF (IgG, Albumin).  PI: Kathleen Poston

EGF

  1. Unbiased Approaches to Novel Biomarker Discovery in Parkinson's Disease-Immunoassay-Plasma (ApoA1, EGF).  PI: Alice Chen-Plotkin

ApoA1

  1. Unbiased Approaches to Novel Biomarker Discovery in Parkinson's Disease-Immunoassay-Plasma (ApoA1, EGF).  PI: Alice Chen-Plotkin

NeuroX

  1. Bridging the Gap between Genetic and Biomarker Cohorts-Harvard Biomarker Study-NeuroX.  PI: Clemens Scherzer
     
  2. Genome Wide SNP Analysis in Parkinson's Disease-NeuroX.  PI: Andy Singleton

RNAseq

  1. Blood RNA Biomarkers of Parkinson's Disease and Progressive Supranuclear Palsy-qRT-PCR.  PI: Judith Potashkin
     
  2. Large Scale Biomarker Discovery and Validation for Parkinson's Disease- RNA-seq-CSF.  PI: Jing Zhang

Methylation

  1. Identification of Epigenetic Signatures in Blood as Biomarkers for Parkinson's Disease-Infinium-Whole blood(DNA Methylation).  PI: Paula Desplats

Proteomics

  1. Biomarker Discovery and Validation in Parkinsons Disease-Mass Spec-CSF(Proteomics).  PI: Ted Dawson & Akhilesh Pandey
     
  2. Towards a Blood-Based Diagnostic Panel for Confirmation of Parkinson's Disease-Somalogic-Plasma.  PI: Alice Chen-Plotkin
     
  3. Large Scale Biomarker Discovery and Validation for Parkinson's Disease-Somalogic-CSF.  PI: Jing Zhang

Peptides

  1. Peptide Biomarkers for Parkinson Disorders.  PI: Jing Zhang

Sphingolipids

  1. Evaluation of Glucocerebrosidase Pathway Biomarkers in Parkinson Disease-Mass Spec-Plasma/CSF (Sphingolipidomics).  PI: Rachel Saunders-Pullman
     
  2. GBA Meta-Analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD-Mass Spec-Plasma(Sphingolipid).  PI: Clemens Scherzer
     
  3. GBA Pathway Markers for Lewy Body Dementias-Mass Spec-Plasma(Sphingolipid).  PI: Clemens Scherzer

Metabolomics

  1. Metabolomics and Risk of Parkinson's Disease-Mass Spec-Blood (Metabolomics).  PI: Alberto Ascherio
     
  2. Metabolic Biomarkers of the Presymptomatic Phase of PD-NMR-Serum (Metabolomics).  PI: Sabrina Boulet